This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dow 30 Stock Roundup: Nike, Walgreens Boots Earnings Impress
by Swarup Gupta
The Dow suffered a particularly tough week, weighed down by a number of concerns.
Aduro Stock Surges on STING Activator Deal With Eli Lilly
by Zacks Equity Research
Aduro (ADRO) inks a collaboration/license deal with Eli Lilly to develop novel immunotherapies for autoimmune and other inflammatory diseases by leveraging its cGAS-STING inhibitor platform.
The Zacks Analyst Blog Highlights: Walmart, Pfizer, Adobe, Johnson & Johnson and IBM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, Pfizer, Adobe, Johnson & Johnson and IBM
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $130.42, marking a +0.99% move from the previous day.
What's In Store for GE in 2019? & Tuesday's Trending Stocks: TLRY, JNJ, ORCL
by Ryan McQueeney
Ryan McQueeney recaps news involving the U.S. housing market, Tilray, Johnson & Johnson, and Oracle. Later, the host provides an outlook for General Electric stock in 2019.
Healthcare ETFs Sink on JNJ News, ACA Ruling: What???s Ahead?
by Sweta Killa
Healthcare took a hit recently on Johnson & Johnson news and a federal judge ruling. The rough trading also spread into the ETF world.
Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study
by Zacks Equity Research
Eli Lilly's (LLY) Taltz displays superiority over standard of care medicine Humira in a head-to-head study on patients with active psoriatic arthritis.
J&J Okays $5B Stock Buyback Plan, Stock Remains Stressed
by Zacks Equity Research
J&J's (JNJ) board authorizes a $5-billion share repurchase plan. Stock slips 2.9% on Monday, extending a 10% drop on Friday post publication of a controversial Reuters story.
Top Research Reports for Walmart, Pfizer & Adobe
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), Pfizer (PFE) and Adobe (ADBE).
J&J Dips 10% as Reuters Says Company Knew of Asbestos in Talc
by Zacks Equity Research
A Reuters article says that J&J (JNJ) knew for decades that its baby powders contained asbestos. J&J stock dips 10%.
Zacks Investment Ideas feature highlights: Johnson and Johnson
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Johnson and Johnson
5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019
by Zacks Equity Research
The big drug stocks are on a strong footing of late. Here are five such picks from the biotech and large-cap pharma space that are expected to do well in 2019 too.
Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.
Johnson and Johnson Shares Rocked by Asbestos Allegations
by David Borun
Shares fall 10% on reports company executives knew about harmful contamination
J&J's Tremfya Beats Novartis' Cosentyx in Head-to-Head Study
by Zacks Equity Research
J&J's (JNJ) psoriasis drug Tremfya proves to be better than Novartis' Cosentyx in phase III head-to-head study for treating adult patients with moderate to severe plaque psoriasis.
Mallinckrodt's Roxicodone Reformulation Gets CRL From FDA
by Zacks Equity Research
Mallinckrodt (MNK) receives complete response letter from the FDA related to its regulatory application seeking approval for abuse-deterrent reformulation of opioid painkiller, Roxicodone.
Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug
by Zacks Equity Research
Eli Lilly (LLY) signs a deal with AC Immune to jointly develop Morphomer tau aggregation inhibitors, which have the potential to treat Alzheimer's disease (AD) and other neurodegenerative diseases.
5 Dow Stocks Stand Tall Despite Index's Loss of 2018 Gains
by vidya Nair
The Dow portfolio has depicted weak trends in 2018, thanks to concerns surrounding trade and interest rates. Nevertheless, strong U.S. economic fundamentals are likely to aid revival.
5 Dow Stocks Defying the Index's YTD Plunge
by Nalak Das
The Dow 30 has been witnessing volatility in 2018 so far on account of investors' apprehension regarding investing in risky assets like equities.
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $147.10, marking a +0.41% move from the previous day.
Portola (PTLA) Down as CHMP Defers Review Date for Ondexxya
by Zacks Equity Research
The CHMP postpones the review timeline of Portola's (PTLA) Ondexxya (in the EU. Shares take a hit.
Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800
by Zacks Equity Research
Bristol-Myers (BMY) enters into a collaboration agreement with Vedanta Biosciences to study Opdivo clubbed with the latter's VE800 for treating patients with advanced or metastatic cancers.
The Zacks Analyst Blog Highlights: Apple, DowDuPont, Exxon Mobil, Johnson & Johnson and Verizon Communications
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, DowDuPont, Exxon Mobil, Johnson & Johnson and Verizon Communications
A Tough Start to December as Stocks Slide Again
by David Borun
China, Brexit and generally uncertainty contribute to another decline in US equities
Pharma Stock Roundup: Glaxo's TESARO Buyout & Horlicks Sale, ASH Cancer Data Updates
by Zacks Equity Research
Glaxo (GSK) to buy TESARO and divest Horlicks brand to Unilever. ASH cancer presentations grab headilines.